clinical trial · NCT02650401
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Hoffmann-La Roche·phase2·active not recruiting·n = 69
Solid TumorsCNS TumorsEntrectinib
brief summary
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
started
May 3, 2016
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
Mar 25, 2026
official title
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol